Greater Cannabis Company, Inc. 10-Q — AI Bull & Bear Analysis

The 10-Q filing paints a picture of a company at a critical crossroads, balancing a promising scientific pivot against a near-total lack of liquidity. While the transition to a biotech-focused model reduces the overhead associated with traditional cannabis cultivation, it does not solve the immediate need for working capital. The company has successfully cleaned up some legacy accounting issues and reduced its quarterly burn, but it remains fundamentally dependent on external financing to survive. For investors, the impact of this filing is binary. The potential for a breakthrough in neuropsychiatric treatment provides a theoretical path to massive valuation expansion, but the current balance sheet suggests a high probability of further dilution or insolvency. The focus now shifts to whether the company can successfully secure the $1.5 million required to stabilize operations and fund the clinical program spearheaded by Dr. Aran.